Stockscreener 앱 받기
0.2842
1.00%
0.0028
Bioaffinity Technologies Inc 주식(BIAF)의 최신 뉴스
BIAFbioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 - Revista ADVFN
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence - Revista ADVFN
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung - Yahoo Finance
Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Grows By 58.8% - Defense World
bioAffinity Receives Nasdaq Non-Compliance Notice - TipRanks
BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors - Insider Monkey
BioAffinity Technologies Announces New U.S. Patent For Novel Broad Spectrum Cancer Therapeutics - marketscreener.com
BIAF Gains New Patent for Innovative Cancer Treatment Method | B - GuruFocus
Revolutionary Cancer Treatment Patent: bioAffinity's New Therapy Kills Cancer Cells While Sparing Healthy Ones - Stock Titan
bioAffinity Technologies Enters Sales Agreement with WallachBeth - TipRanks
bioAffinity Technologies (NASDAQ:BIAF) Trading Down 3.1% – What’s Next? - Defense World
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline - MSN
bioAffinity Technologies names new chief medical officer By Investing.com - Investing.com South Africa
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer - citybiz
BioAffinity Technologies (BIAF) Appoints Gordon Downie as Chief Medical Officer | BIAF Stock News - GuruFocus
bioAffinity Technologies names new chief medical officer - Investing.com Australia
From Olympic Bronze to Cancer Breakthrough: bioAffinity Names Elite Physician as New CMO - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
bioAffinity Technologies Sets 2025 Annual Meeting Date - TipRanks
bioAffinity Technologies Reports Strong Q1 2025 Growth - MSN
bioAffinity Technologies, Inc. SEC 10-Q Report - TradingView
bioAffinity Technologies Reports First Quarter 2025 Results - Business Wire
bioAffinity Technologies Completes $3.2M Public Offering - TipRanks
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering - The Malaysian Reserve
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer - Stock Titan
bioAffinity announces $3.25 million securities offering By Investing.com - Investing.com Nigeria
bioAffinity Technologies completes $3.25 million offering By Investing.com - Investing.com South Africa
BioAffinity Technologies Closes $3.25 Million Offering - marketscreener.com
bioAffinity Technologies (BIAF) Completes $3.25M Securities Offering | BIAF Stock News - GuruFocus
bioAffinity Technologies completes $3.25 million offering - Investing.com
bioAffinity Technologies Announces Closing of $3.25 Million Offering - Bluefield Daily Telegraph
bioAffinity Technologies Boosts Data Acquisition for CyPath Lung Test - Medical Product Outsourcing
BioAffinity Technologies announces pricing of $3.25M offering - Yahoo Finance
Crude Oil Rises Sharply; US Trade Deficit Widens In March - Benzinga
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering - Eastern Progress
The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies - NewsBreak: Local News & Alerts
Cancer Detection Biotech bioAffinity Secures Fresh $3.25M Funding: Key Details of Latest Stock Offering - Stock Titan
bioAffinity announces $3.25 million securities offering - Investing.com Australia
Dow Falls Over 250 Points; Marriott Posts Upbeat Earnings - Benzinga
bioAffinity Technologies Announces Pricing of $3.25 Million Offering - Business Wire
Top Stock Reports for Alphabet, Berkshire Hathaway & Visa - Yahoo Finance
Japanese startup ‘Craif’ raises US$22M to bring urine cancer biopsy to the U.S. - Mugglehead Magazine
bioAffinity Technologies (NASDAQ:BIAF) Shares Up 2.7% – Still a Buy? - Defense World
bioAffinity Technologies streamlines lung cancer detection test By Investing.com - Investing.com Canada
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost - BioSpace
0.40%
1.06%
자본화:
|
볼륨(24시간):